Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy

Vaccine

Volumn 32, Issue 9, 2014, Pages 1031-1035

  Lu, Ching Lan ^a   Chang, Sui Yuan ^b   Chuang, Yu Chung ^a   Liu, Wen Chun ^a   Su, Chin Ting ^b   Su, Yi Ching ^b   Chang, Shu Fang ^b   Hung, Chien Ching ^a,c,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hyporesponsiveness; Immunization; Immunogenicity; Pneumococcal vaccination; Streptococcus pneumoniae

Indexed keywords

HYPORESPONSIVENESS; IMMUNIZATION; IMMUNOGENICITY; PNEUMOCOCCAL VACCINATION; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; SUPERIOR SAGITTAL SINUS; VIRAL LOAD;

EID: 84895063141     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.009     Document Type: Article

References (21)

1. Nuorti J.P., Butler J.C., Gelling L., Kool J.L., Reingold A.L., Vugia D.J. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000, 132(3):182-190.
2. Jordano Q., Falcó V., Almirante B., Planes A.M., del Valle O., Ribera E., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38(11):1623-1628.
3. Heffernan R.T., Barrett N.L., Gallagher K.M., Hadler J.L., Harrison L.H., Reingold A.L., et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005, 191(12):2038-2045.
4. Rodriguez-Barradas M.C., Goulet J., Brown S., Goetz M.B., Rimland D., Simberkoff M.S., et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008, 46(7):1093-1100.
5. Kaplan J.E., Benson C., Holmes K.H., Brooks J.T., Pau A., Masur H., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58(RR-4):1-207.
6. Tasker S.A., Wallace M.R., Rubins J.B., Paxton W.B., O'Brien J., Janoff E.N. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002, 34(6):813-821.
7. Miiro G., Kayhty H., Watera C., Tolmie H., Whitworth J.A., Gilks C.F., et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005, 192(10):1801-1805.
8. Crum-Cianflone N.F., Huppler Hullsiek K., Roediger M., Ganesan A., Patel S., Landrum M.L., et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010, 202(7):1114-1125.
9. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355(9221):2106-2111.
10. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362(9):812-822.
11. Centers for Disease Control and Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61(40):816-819.
12. Concepcion N.F., Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8(2):266-272.
13. Lesprit P., Pedrono G., Molina J.M., Goujard C., Girard P.M., Sarrazin N., et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007, 21:2425-2434.
14. Penaranda M., Payeras A., Cambra A., Mila J., Riera M. Majorcan Pneumococcal Study Group. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010, 24(8):1226-1228.
15. Kroon F.P., van Dissel J.T., Ravensbergen E., Nibbering P.H., van Furth R. Enhanced antibody response to pneumococcal polyaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000, 19(7-8):886-894.
16. Hung C.C., Chang S.Y., Su C.T., Chen Y.Y., Chang S.F., Yang C.Y., et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010, 11(1):54-63.
17. Kumar D., Welsh B., Siegal D., Chen M.H., Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant 2007, 7(3):633-638.
18. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 15 January, 2014.
19. Rodriguez-Barradas M.C., Groover J.E., Lacke C.E., Gump D.W., Lahart C.J., Pandey J.P., et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996, 173(6):1347-1353.
20. Lu C.L., Hung C.C., Chuang Y.C., Liu W.C., Su C.T., Su Y.C., et al. Serologic response to primary accination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother 2013, 9(2):398-404.
21. Lu C.L., Hung C.C., Chuang Y.C., Liu W.C., Su C.T., Hsiao C.F., et al. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. Vaccine 2012, 30(24):3526-3533.